Hemoglobin variability predicts mortality in acute kidney injury patients undergoing continuous renal replacement therapy: a multi-database cohort study

血红蛋白变异性可预测接受连续性肾脏替代治疗的急性肾损伤患者的死亡率:一项多数据库队列研究

阅读:1

Abstract

BACKGROUND: Short-term hemoglobin variability (Hb-ARV) during continuous renal replacement therapy (CRRT) may reflect blood volume instability in acute kidney injury (AKI), yet its mortality implications remain unclear. METHODS: This multi-database study analyzed adult AKI patients receiving CRRT >24 h from the Medical Information Mart for Intensive Care (MIMIC)-IV, eICU Collaborative Research Database (eICU), Amsterdam University Medical Center (AmsterdamUMC) database, and Jiangsu Province Hospital (JSPH) CRRT database. Hb-ARV, quantifying hemoglobin fluctuations during CRRT, was assessed via Cox regression and restricted cubic splines for associations with in-hospital and 1-year mortality. RESULTS: The MIMIC-IV, eICU, AmsterdamUMC, and JSPH cohorts included 1,321, 437, 631, and 488 patients, respectively, with median (IQR) Hb-ARVs of 5.1 (3.9-6.6) g/L, 5.8 (4.1-8.2) g/L, 5.0 (3.9-6.8) g/L, and 6.3 (5.1-8.0) g/L. In-hospital mortality rates were 48.2%, 41.2%, 43.7%, and 44.9%. Restricted cubic splines revealed J-shaped/linear mortality trends with Hb-ARV. Compared to the second quartile of Hb-ARV, the highest quartile was significantly associated with increased in-hospital mortality in MIMIC-IV (adjusted HR 1.32, 95% CI: 1.05-1.66), AmsterdamUMC (adjusted HR 1.74, 95% CI: 1.23-2.46), and JSPH (adjusted HR 1.96, 95% CI: 1.31-2.93) cohorts. In the eICU cohort, where a linear trend was observed, each 1 g/L increase in Hb-ARV was associated with an adjusted HR of 1.07 (95% CI: 1.03-1.11) for in-hospital mortality. Highest quartile of Hb-ARV was also associated with increased 1-year mortality in MIMIC-IV and AmsterdamUMC cohorts. CONCLUSIONS: Excessive Hb-ARV during CRRT predict higher short- and long-term mortality in patients with AKI.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。